Praxis precision medicines to participate in upcoming april conferences

Boston, april 03, 2025 (globe newswire) -- praxis precision medicines , inc. (nasdaq: prax), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (cns) disorders characterized by neuronal excitation-inhibition imbalance, today announced that it will be participating in two upcoming investor conferences this april:
PRAX Ratings Summary
PRAX Quant Ranking